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Background: Economic evaluations to inform decisions about allocation of health resources are scarce in Low and
Middle Income Countries, including in Sri Lanka. This is in part due to a lack of country-specific utility weights,
which are necessary to derive appropriate Quality Adjusted Life Years. The EQ-5D-3L, a generic multi-attribute
instrument (MAUI), is most widely used to measure and value health states in high income countries; nevertheless,
the sensitivity of generic MAUIs has been criticised in some conditions such as cancer. This article describes a
protocol to produce both a generic EQ-5D-3L and cancer specific EORTC-8D utility index in Sri Lanka.
Method: EQ-5D-3L and EORTC-8D health states will be valued using the Time Trade-Off technique, by a
representative population sample (n = 780 invited) identified using stratified multi-stage cluster sampling with
probability proportionate to size method. Households will be randomly selected within 30 clusters across four
districts; one adult (≥18 years) within each household will be selected using the Kish grid method.
Data will be collected via face-to-face interview, with a Time Trade-Off board employed as a visual aid. Of the 243
EQ-5D-3L and 81,290 EORTC-8D health states, 196 and 84 respectively will be directly valued. In EQ-5D-3L, all health
states that combine level 3 on mobility with either level 1 on usual activities or self-care were excluded. Each
participant will first complete the EQ-5D-3L, rank and value 14 EQ-5D-3L states (plus the worst health state and
“immediate death”), and then rank and value seven EORTC-8D states (plus “immediate death”). Participant
demographic and health characteristics will be also collected.
Regression models will be fitted to estimate utility indices for EQ-5D-3L and EORTC-8D health states for Sri Lanka.
The dependent variable will be the utility value. Different specifications of independent variables will be derived
from the ordinal EQ-5D-3L to test for the best-fitting model.
Discussion: In Sri Lanka, a LMIC health state valuation will have to be carried out using face to face interview
instead of online methods. The proposed study will provide the first country-specific health state valuations for Sri
Lanka, and one of the first valuations to be completed in a South Asian Country.
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The economic evaluation of health interventions has
become an integral part of health policy and decision
making for the allocation of limited healthcare resources
[1]. The objective of economic evaluation is to provide
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reproduction in any medium, provided the oreconomic evaluation has to identify, measure, value, and
compare the costs and consequences of the alternatives
being considered. Many high income countries perform
economic evaluations and health technology assessments
to facilitate informed decisions to allocate healthcare re-
sources. The common outcome measures used in health
economic evaluations are Quality Adjusted Life Years
(QALYs) and Disability Adjusted Life Years (DALYs).
However, most western European and Australian health
advisory institutions recommend QALYs as the preferred
outcome measure [2-4]. Moreover, unlike DALYs, QALYsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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derived from the preferences of a population sample
for being in a given health state. Preference elicitation
exercises to derive utility weights ideally use health
states described by Multi Attribute Utility Instruments
(MAUIs). Examples of MAUIs are the three and five
level EUROQoL 5 Dimensions (EQ-5D-3L the EQ-5D-5L)
[5,6], Short Form 6D (SF-6D) [7], three Health Utilities
Indices [8], and Assessment of Quality of Life (AQoL)
[9]. Commonly used preference elicitation techniques
to value the health states of the MAUIs are the Time
Trade-off (TTO), Standard Gamble (SG) and, more
recently, Discrete Choice methods [10].
Low and middle income countries and Sri Lanka
The World Bank classifies countries according to their
annual per capita income as low income (US$ 1025 or less
in 2011), lower middle income (US$ 1026–4035), upper
middle income (US$ 4036–12,476), and high income
(above US$ 12,476) [11]. A Low Middle Income Country
(LMIC) is defined as a country with low, lower middle or
upper middle income [11]. In LMICs such as Sri Lanka, the
availability of utility weights is of considerable importance
as these countries require greater efficiency of health care
resource allocation due to scarce resources and a high
disease burden [12]. The availability of utility weights
could facilitate cost-utility analyses (CUA) and consequently
improved efficiency in allocating health resources in these
countries. Utility weights, derived from the preferences of a
population of a given country, have been reported to be
different from those derived from other countries [13,14].
Moreover, widely different socioeconomic, cultural and so-
cial conditions between high income countries and LMICs
make it imperative that country-specific utility weights be
derived and used in economic evaluations.
A recent literature review showed there have been few
health state valuations undertaken in LMICs, impeding
the development of CUAs in these countries [15]. Where
health state valuations have been undertaken, the EQ-5D-
3L is the most commonly applied MAUI to describe health
states in valuation studies in the LMIC context. The use
of validated methodologies and increased collaboration
between high income countries and LMICs is required to
build capacity for health state valuation and health eco-
nomic research in LMICs [15]. Sri Lanka, a South Asian
country, does not have any health state valuations for
MAUIs available to date. Developing a utility value set for
Sri Lanka is important to promote economic evaluations
that are based on country-specific preferences. In addition,
developing a value set by trialling a feasible, valid method-
ology for health state valuations in a LMIC environment
is an important step forward in progressing knowledge to
enable further health state valuations to be undertaken in
the LMIC context.Barriers to health state valuation in LMICs
LMICs such as Sri Lanka need to improve the efficiency of
their health systems. Health state valuation is a crucial
element to improve health outcomes to identify efficient
healthcare interventions. However, it is challenging for a
country like Sri Lanka to undertake health state valuation
exercises as it lacks health economics expertise. Further, un-
like a high income country, health state valuations cannot
be undertaken in LMICs using online surveys due to low
internet use and low computer literacy. Thus, health state
valuations must involve a community sample and manual
data collection processes utilising trained data collectors.
This can involve large distances travelled over difficult ter-
rain to reach diverse communities to ensure representative-
ness of the sample to the population. Nevertheless, low
research costs in LMICs facilitate such data collection exer-
cises, provided the necessary expertise is available for
research leadership and collaboration. Another perceived
obstacle is the potential difficulty for the average person
from a LMIC to understand the concept of a trade-off of life
in health state valuations. That is, there may be concerns
about religious and cultural acceptability of trades between
health states and life. Given the lack of available health state
valuations and economic expertise in Sri Lanka the readi-
ness of policy makers and the clinical fraternity to accept
the concept of utility weights in healthcare decision making
is as yet unproven.
The need for LMIC specific utility value sets
Despite the potential barriers to undertaking valuation stud-
ies in LMICs, the development of health state valuations in
Sri Lanka is a necessary step to enable an expansion and un-
derstanding of the potential role of economic evaluation in
health care decision-making. Although the common avail-
ability of DALY weights for LMICs may raise the question of
why LMICs need utility weights for MAUIs, it is important
to remember that the weights developed for use to derive
DALYs are not country specific [16]. Yet, resource allocation
decisions within a LMIC are country specific. Therefore,
country specific utility weights for MAUIs are necessary to
derive QALYs to guide resource allocation decisions within
any one country, such as Sri Lanka. It is well known that
utility weights differ even between high income countries
[13] and arguably might be expected to differ to a greater ex-
tent between high income countries and LMICs. Preferences
to avoid a health state can depend on the health care avail-
able, the culture and social support [17]. For these reasons,
country specific weights reflecting the preferences of the
population are required for LMICs including Sri Lanka.
Generic vs disease specific multi-attribute utility
instruments (MAUIs)
There are situations where generic MAUIs like the
EQ-5D-3L cannot be applied. A major issue is lack of
Kularatna et al. Health and Quality of Life Outcomes 2013, 11:149 Page 3 of 8
http://www.hqlo.com/content/11/1/149sensitivity of generic MAUI for some disease conditions like
cancer [18]. As a result, disease specific MAUIs have been
validated [18]. Sri Lanka has a high disease burden of
cancer [19], for which this protocol describes valuation of
health states of cancer specific MAUIs alongside the EQ-
5D-3L. Generic instruments are more suitable to calculate
utility weights for CUA. Disease specific instruments would
help in the rational allocation of resources within a disease,
and patients and clinicians specialising in that disease could
use these tools to evaluate treatment regimens and any im-
provements in quality of life. In contrast, generic instru-
ments would help decision makers to make decisions on
healthcare resource allocation nationally.
Aim of the study
To date, no health state valuation study has been under-
taken in Sri Lanka or any other South Asian country using
a generic MAUI for a representative population sample.
Thus, this protocol reports the methods for a health state
valuation study to be undertaken in Sri Lanka. The study
will derive utility weights for the health states described by
the EQ-5D-3L [20], a generic MAUI, and the EORTC-8D
[18], a cancer specific MAUI. Moreover, the proposed study
will facilitate future research exploring the theoretical ques-
tion of differences between utilities produced from health
states of generic and disease specific MAUIs.
Methods
The time trade-off (TTO) and standard gamble (SG) [21]
are the most widely used methods to value health states
[10]. A visual analogue scale (VAS) has also been used to
produce national value [22] sets, but this does not involve
a trade-off. Dolan et al. [23] concluded that the TTO fared
slightly better than SG in valuing EQ-5D. Since 1995, the
majority of EQ-5D valuations have used the TTO as their
preferred elicitation method. Moreover, whilst both TTO
and SG are complex tasks, Torrance et al. [24] concluded
that the TTO is more easily administered to the general
public. More recently, the discrete choice experiments
(DCE) method has been used to value health states
[6,10,25]. However, there is as yet little experience using the
DCE to produce a national value set even in high income
countries. Consequently, the TTO method will be used to
elicit preferences from a representative general population
sample. Ethical clearance for this study has been granted by
the Griffith Human Research Ethics Committee as well as
the Sri Lanka Medical Association Ethics Committee.
EQ-5D-3L
The EQ-5D-3L has been widely used to describe and
value health states in a large number of countries including
the UK [23], Spain [14], Germany [26], Australia [20], USA
[27], Japan [28], Argentina [29], Chile [30], Thailand [31]
and Zimbabwe [32]. Moreover, the reliability and validity ofthe EQ-5D-3L as a MAUI has been widely established
[13,33-38]. The EQ-5D-3L has a total of 243 health states
making it relatively easy for valuation; a recent study
showed it is feasible to directly value almost the full set
of EQ-5D-3L health states [20]. A health state described
using the EQ-5D-3L is relatively easy to understand for
the participant as it has only five dimensions and three
levels in each dimension. Using EQ-5D-3L MAUI full
health is described as 11111, stating there are no problems
in mobility, personal care, usual activities, no pain/discom-
fort and no anxiety/depression. The worst imaginable
health state according EQ-5D-3L is 33333. In 33333, a per-
son is confined to bed, unable to wash or dress self, unable
to perform usual activities, has extreme pain and dis-
comfort and is extremely anxious or depressed.
EORTC-8D
Parallel use of the EORTC-8D is proposed in this study to
inform the debate on the lack of sensitivity of EQ-5D-3L
for conditions like cancer. The EORTC-8D is a MAUI for
cancer newly derived from the EORTC QLQC-30 question-
naire [18]. It has eight dimensions with four or five levels in
each dimension. The EORTC-8D can produce 81,290
health states. Out of this large number, only 84 health states
will be valued in the present study [18]. EORTC-8D health
states will be divided into seven groups of 12. Each partici-
pant will value the allocated seven health states plus imme-
diate death. Only one value set from the UK is currently
available for the EORTC-8D [18].
Selection of health state for valuation
Out of the 243 EQ-5D-3L health states, 196 (plus 11111
and 33333) will be directly valued using TTO methods
[20]. A state of “immediate death” will also be used in the
valuation. Excluded health states were considered implaus-
ible if level 3 on mobility was combined with level 1 on
either usual activities or self-care [20]. The selected 196
health states were randomly divided into 14 groups each
containing 14 health states, with each participant valuing
one group of 14 health state, as well as “the pits” (33333),
the state of “immediate death” and full health (11111).
Interview procedure
Health states will be directly valued in a face-to-face
interview. Interviews will be conducted by eight trained
data collectors. Interviewers will be university students.
They will be trained by a health economic research team
from Australia. At the start of the interview, the data
collector will describe the purpose of the study and obtain
informed consent. The participant will then complete a
questionnaire consisting of demographic information and
past clinical experience. The language will be English or
Sinhalese. Subsequently, an EQ-5D questionnaire will be
given to the participant, asking them to rate their current
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their current health. It is a thermometer-like scale from
0–100, where 0 is worst imaginable health state for the
participant and 100 the best imaginable.
Participants will then asked to rank 16 health states
(14 health states plus 33333 and immediate death). They
will then be asked to undertake the TTO valuation of
15 health states (14 health states plus 33333). State of
full health (11111) will be used to compare with the each
valuing health state [39] in the TTO procedure. After the
ranking is recorded, health states will be given to the par-
ticipant in a random order. The TTO procedure will be
conducted as explained by Gudex [40].
For each health state, participants will first be given a
choice between immediate death or living in the given
health state for ten years followed by immediate death
[40], to define which states are considered better/worse
than death and consequently which side of a TTO board
will be used as a visual aid. For states better than death,
a middle value of five years will be offered in full health
instead of ten years in the given health state. According to
each participant’s response, participants will be offered
further trade-offs using the outward titration approach
[40]. In this approach, the time spent in full health will
be increased or decreased in increments of one year.
When there is agreement and refusal between two full
years midpoint of the two will be offered. As an ex-
ample, if a respondent agreed to 3 years of full health
instead of 10 years in the given health state and refused
2 years of full health, then 2.5 years of full health will
be offered as the trade-off. For states better than death,
the TTO value is calculated as x/10, where x is the time
the participant agrees to spent in full health instead of
10 years in the given health state.
For states worse than death, an alternative of immedi-
ate death will be compared with a combination of living
in the given health state and full health followed by
death. The total duration will be 10 years. If the time
spent in the given health state is x and time spent in full
health is y , the TTO value is calculated as ((x/10) -1),
ensuring negative values given by states worse than
death will have a lower bound of −1.
Following the TTO valuation for EQ-5D health states,
the data collector and participant will take a 15 minute
break and then value the seven EORTC-8D health states
(plus immediate death). The participant will first rank
the health states in ascending order, and then provide
TTO values for states in random order, using a similar
process to that described for the EQ-5D-3L states.
Sampling
A stratified, cluster sampling technique with random selec-
tion within clusters will be used to select a representative
sample from Sri Lankan population.Sample size
The desired precision of results and the representativeness
of the sample were both considered to inform the required
sample size. Six months will be the smallest time incre-
ment used in the TTO valuation of health states. Using
80% power, a sample size calculation was carried out to
determine the sample size needed to identify six month
increments (Equation 1) [41].
N ¼ 2 SD
2
MCID2
 δ Sig þ powerð Þð Þ2 ð1Þ
In equation 1, N is the sample size and the minimum
clinically important difference (MCID) is the minimum
TTO increment. Pickard et al. [42] reported the MCID
for EQ-5D-3L health states as 0.06-0.07 in a study on
cancer. However, for the present calculation, a more
conservative MCID of 0.05 was used as six months was
minimum increment in the TTO (i.e. 0.5/10). Where 0.5
is a half year and 10 is 10 years of time horizon given for
health state valuations. Moreover, use of 0.05 gives higher
sample size than 0.06 or 0.07. The weighted mean stand-
ard deviation (SD) (0.26) of Thailand [31] and Argentina
[29] value sets was used for the equation. The meaning of
δ is values for significance (Sig) and power is to be as-
sumed from a normal distribution table. By convention,
significance was considered at p < 0.05 and power was
80%, and assumed to follow a normal distribution [41]. To
compensate for the inefficiency of data being not normally
distributed, the power calculation was adjusted by 1/0.95
[41]. Sample size (N) was calculated as 445 with 80%
power of detecting a difference of six months in TTO val-
uations with a 5% significance based on 0.26 SD.
A second sample size calculation (Equation 2) [43] was
carried out to determine the sample size needed for
the participants to be considered representative of the
Sri Lankan population.
N ¼ z
2p 1−pð Þ
e2
ð2Þ
Sample size (N) was calculated as 385 with 95% con-
fidence level (Z), 50% maximum response distribution
rate (p), 5% margin of error (e).
Thus, the higher sample size of 445 can be considered
as representative of the general population. To compen-
sate for the loss in efficiency from cluster sampling, the
sample size was increased by the “design effect” factor
(Equation 3) [44]. Thus, the design effect was calculated
for the selected sample size of 445 [45].
D ¼ 1þ b−1ð Þρ ð3Þ
Design effect (D) is increased when the cluster size (b)
and/or rate of homogeneity (ρ) is increased. More precisely,
ρ is explained as a measure of variability between clusters
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there is reason to assume the condition of interest would
produce higher variability between clusters, ρ would
increase and the corresponding sample size would increase.
Instead, if the condition of interest would produce less
variability between clusters, ρ would be closer to zero.
In such cases Bennet et al. [45] recommend using a
value for ρ of 0.02. This recommendation was followed
in the present calculation. This is a reasonable assump-
tion because individuals in each cluster will value the
same health states.
There is no clear instruction in the literature for
choosing a cluster size. When the cluster size increases
sample size increases. However, smaller cluster size means
more clusters. More clusters present logistic constraints.
It was decided to employ a balance between these two
extremes by choosing a cluster size of 30, which gives a
sample size of 703 for ρ of 0.02. The number of clusters
for that sample size is 23 (Table 1).
In Sri Lanka, the non-response rate in a previous com-
munity survey questioning participants comprehensively
on health care use has been estimated to be less than 10%
[46]. Thus, a non-response rate of 10% was assumed, and
the a final sample size of 773, rounded up to 780, will be
invited to participate Thus, 26 clusters of 30 will be used
to collect data from the Sri Lankan population.
Sample selection
A stratified, cluster sampling technique with probability
proportionate to size (PPS) was used to select study
participants [44]. For pragmatic reasons, four districts
were selected from the 25 districts of Sri Lanka. These
are Colombo, Kalutara, Kandy and Kurunegala. These
districts were selected as they represent a good mix of
suburban and rural areas and are logistically feasible
for the proposed data collection. A district in Sri Lanka is
divided into Medical Officer of Health (MOH) areas, each
of which is further divided into Public Health Midwife
(PHM) areas. PHM areas will be the primary cluster.
According to population proportions, 26 clusters were
divided among the four districts. In each district, sam-
pling interval was calculated by dividing the total districtTable 1 Different sample sizes with variable cluster size
and design effect for initial sample size of 445
(using the sample size produced from power calculation)
Cluster size Ρ
0.02 (n of cluster) 0.09 0.5
20 614 (31) 1205 4672
30 703 (23) 1606 6897
40 792 (20) 2006 9122
50 881 (18) 2407 11347
ρ–rate of homogeneity.population by the number of clusters [45]. Primary
clusters were listed alphabetically in each district. Popu-
lation and cumulative population of primary clusters
were listed. Starting with a randomly generated number
(below the sampling interval) and sampling interval,
systematic selection of primary clusters will be selected
for each district. Using this probability proportionate to
size (PPS) method, the probability of selecting any cluster
varies with the size of the cluster, giving larger clusters a
greater probability of selection and smaller clusters a
lower probability [27]. PPS produces a sample which is
self-weighted, leading to simplified analysis. As the
cluster size is a constant [30] in the present study, each
household in the population will have an equal probability
of being selected.
In each primary cluster (PHM area), random selection
was used to select 30 households by electoral address
list. People living in institutions, paid accommodation
(boarding houses, Inns) and elderly homes will be excluded.
If the selected address is found to be from an excluded
category, the data collector will be supplied with a new
randomly selected address. If the data collector visits a
selected address and gets no answer, they will visit
again until they are finished with the cluster. If a se-
lected address is permanently unoccupied during that
duration or the occupant does not give consent, it is
considered a non- participant and no new selection will
be carried out in its place.
Only one eligible adult will be systematically selected
to participate per household, according to the Kish grid
[47] method (Table 2). Eligible adults are those who are
18 years and older, who can give consent and who routinely
sleep at the household even if they are absent at the time of
the first visit. Eligible adults will be ordered from youngest
to oldest, and the participant selected according to the
household number and number of eligible participants.
After the selection of the interviewee using the Kish grid
[47] method the data collector will complete the interview
immediately or arrange an appointment at a convenient
time for the selected participant.
Data collector training
Eight undergraduates studying a health-related degree
will be employed for data collection. All interviewers will
be trained in ethics and survey methods as a group in
a workshop environment. They will be introduced to
the questionnaire capturing demographic information,
EQ-5D-3L and EORTC-8D instruments, and the TTO
technique. They will undergo closely supervised training in
TTO health valuation, including experiential practice-based
learning over a two week period. At the end of the training
data collectors should be able to explain the objective of
the study to a participant, explain the consent conditions
and carry out the TTO valuation. A trainer will assess each
Table 2 Selection of households using Kish grid
Household no in
a given cluster
Number of eligible adults per household
1 2 3 4 5 6 or more
1-5 1 1 3 2 5 1
6-10 1 2 1 3 4 2
11-15 1 1 2 4 1 3
16-20 1 2 3 1 2 4
21-25 1 1 2 1 3 5
26-30 1 2 1 4 3 6
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team of investigators and data collectors will discuss and
rectify any challenges in the questionnaires, information
sheet, and procedure.
Validity and reliability
The validity of the instruments will be ensured with the
use of the validated Sinhalese version of the EQ-5D-3L
in constructing EQ-5D-3L health states. The EORTC-8D
health states will be constructed with the aid of its parent
instrument the EORTCQLQ-C-30 for which a Sinhalese
version has been validated in Sri Lanka [48]. Permissions
were obtained from the developers to use the validated
EQ-5D and EORTC-8D/EORTCQLQC-30 instruments.
The selection of instruments for data collection was
used after a thorough literature survey which examined
contemporary methods of health state valuations in
LMIC. Moreover, content validity of the instruments used
for data collection was further strengthened by agreement
between the research team for the use of proposed health
states valuation instruments and other questionnaires used
in the survey.
Reliability of the data will be ensured by rigorous
training of data collectors in Sri Lanka to ensure they
are familiar with the data collection instruments and
competent in delivering interviews using the TTO method.
Moreover, the data collection will constantly be monitored
by the investigators. Investigators will visit 10% of the
randomly selected sample after data collection and
ensure randomly selected person was actually selected
for data collection. At the end of each day, completed
forms will be collected by investigators from the data
collectors. Furthermore, randomly selected 40% of data
entry will be verified by the investigators.
Plan for analysis
Demographic characteristics of the sample and a descriptive
analysis of participants’ own health status and medical
conditions will be examined and compared to national data.
For each directly valued EQ-5D-3L or EORTC-8D health
state, utility values will be calculated for each participant.
Data will be tested for normality and assessed graphically.Mean, standard deviation of TTO values and, if applicable,
median and interquartile ranges will be reported. Multi-
level modelling will be used to examine the design effect
of the sample. Intra-class correlation will be examined
to determine the percentage of variance explained by
each level of the cluster sampling. Generally more than
10% of the variance needs to be in each level to warrant
multi-level modelling.
If not, generalised least square models with random
effects will be fitted. Models will be fitted separately for
utility and disutility as the dependent variable. Main effect
model [49], main effects with N3 [49] and main effects with
each pairwise interaction [20] will be tested. Models will be
compared for goodness of fit using log likelihood, likelihood
ratio test, Akaike Information Criteria (AIC) [50] and
Bayesian Information Criteria (BIC) [51]. Sri Lankan
EQ-5D-3L value set will be estimated from the selected
best fitting model. Using the same methods separate
models will be specified for EORTC-8D data to estimate
EORTC-8D value set for Sri Lanka.
Sub group analysis will be carried out to identify variables
that drives health state valuation [13] in general population
in Sri Lanka. The effect of religious practices and beliefs,
income, education and disease experience in self or close
family will be examined.
Discussion
This study will be one of the first studies to derive a utility
value set for either the EQ-5D-3L or EORTC-8D value sets
based on the preferences of a representative population
from a LMIC. To our knowledge, it will also be the first
health state valuation study undertaken in a South Asian
country. As such, this study makes two important contri-
butions. First and foremost, it will produce health state
value sets for the generic EQ-5D-3L and disease specific
EORTC-8D for use in Sri Lanka. Future health economic
evaluations can be carried out using the resulting utility
weights specific to Sri Lanka, enabling country specific
estimates of the cost-effectiveness of health care interven-
tions to be used by health care decision makers. Secondly,
by innovatively applying health state valuation methods in
the new context of a LMIC (specifically to assess the pref-
erences of a sample of the Sri Lankan population), the
current protocol will provide insights into the feasibility of
health state valuation methods in the LMIC context.
The protocol outlines the justification for using utility
values in LMICs, selection of EQ-5D-3L and EORTC-8D
health states, the TTO exercise, sample size calculation,
sample selection and approach to face to face interview of
participants. The proposed study will contribute to closing
the gap in health state valuation between LMICs such as
Sri Lanka and high income countries where these studies
are now routinely undertaken. This study will support
capacity building for health economic research. Moreover,
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South Asian lower middle income country that can be
compared with utility weights of high income countries
and examined for differences. It is proposed that future
research will assess both these differences, as well as
confirm whether the difference in utility found for generic
and cancer specific instruments in high income countries
[52] is also found in for Sri Lanka. More importantly, this
protocol paves the way for future health state valuations
based on the preferences of representative community
samples of the general population in LMICs using local
expertise and minimum resources.
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